SEC Comment Letter 0000000000-24-001478 to ZEVRA THERAPEUTICS, INC. (ZVRA)
ZEVRA THERAPEUTICS, INC.
Date: Feb. 7, 2024 · CIK: 0001434647 · Accession: 0000000000-24-001478
AI Filing Summary & Sentiment
File numbers found in text: 333-276856
Letter
United States securities and exchange commission logo February 7, 2024 R. LaDuane Clifton, CPA Chief Financial Officer, Secretary and Treasurer Zevra Therapeutics, Inc. 1180 Celebration Boulevard, Suite 103 Celebration, FL 34747 Re:Zevra Therapeutics, Inc. Registration Statement on Form S-3 Filed February 5, 2024 File No. 333-276856 Dear R. LaDuane Clifton: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nathan Ajiashvili, Esq.
Show Raw Text
United States securities and exchange commission logo
February 7, 2024
R. LaDuane Clifton, CPA
Chief Financial Officer, Secretary and Treasurer
Zevra Therapeutics, Inc.
1180 Celebration Boulevard, Suite 103
Celebration, FL 34747
Re:Zevra Therapeutics, Inc.
Registration Statement on Form S-3
Filed February 5, 2024
File No. 333-276856
Dear R. LaDuane Clifton:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Nathan Ajiashvili, Esq.